$IMVT News

Last published 2d ago

2d agoIMVTImmunovant, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
2d agoIMVT ROIVImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026GlobeNewswireIMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial
3w agoIMVT ROIVImmunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026GlobeNewswireDURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9,
1mo agoIMVTKuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ:IMVT) breached their fiduciary duties to
2mo agoIMVTKuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT)...
3mo agoIMVT ROIVImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026GlobeNewswireAll IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat
3mo agoIMVT ROIVImmunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026GlobeNewswireDURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before
3mo agoIMVTKuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmGlobeNewswireNEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ:IMVT) breached their fiduciary duties
5mo agoIMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026GlobeNewswireIMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will
6mo agoIMVT ROIVImmunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026GlobeNewswireDURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business
7mo agoIMVTImmunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)GlobeNewswirePhase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated greater levels of
9mo agoIMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025GlobeNewswireIMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept
9mo agoIMVT ROIVImmunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026GlobeNewswireDURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business
11mo agoIMVTImmunovant Announces Pricing of $550 Million Common Stock FinancingGlobeNewswireFunding to provide runway through potential Graves' Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling
1y agoIMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025GlobeNewswireStudy in uncontrolled Graves' disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment dataIMVT-1402 development is progressing with potentially
1y agoIMVT ROIVImmunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025GlobeNewswireNEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m.
1y agoIMVT ROIV ROIVWRoivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease PatientsGlobeNewswireFirst-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal
1y agoIMVTImmunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease PatientsGlobeNewswireFirst-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal
1y agoIMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025GlobeNewswireInitiated a second potentially registrational study of IMVT-1402 in Graves' disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren's disease (SjD), both in June 2025All other clinical trials in
1y agoIMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025GlobeNewswireImmunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD) and a potentially
1y agoIMVTImmunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) StudiesGlobeNewswirePivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in
1y agoIMVTImmunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ProgramsGlobeNewswireNEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host
1y agoIMVT ROIV ROIVWRoivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ProgramsGlobeNewswireNEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host
1y agoIMVTImmunovant Reports Financial Results for the Quarter Ended December 31, 2024GlobeNewswireLead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) now enrolling
1y agoIMVTKuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT)...
1y agoIMVTImmunovant Announces $450 Million Private PlacementGlobeNewswireNEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it has agreed
2y agoIMVTImmunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024GlobeNewswireFive Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate
2y agoIMVTImmunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual MeetingGlobeNewswireNEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from
2y agoIMVTAnkyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of DirectorsBusiness WireAnkyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their
2y agoIMVTImmunovant Provides Update on Graves' Disease Development ProgramGlobeNewswireHigh dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-Free response rate in patients uncontrolled on ATDs at week 12Strong
2y agoIMVTImmunovant to Host Graves' Disease Program Update on September 9, 2024GlobeNewswireNEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will
2y agoIMVTImmunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024GlobeNewswireCompleted enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track for fiscal year end (March 31, 2025) Progressed
2y agoIMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024GlobeNewswireFollowing a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic
2y agoIMVTImmunovant Awarded U.S. Patent for IMVT-1402GlobeNewswireComposition of matter patent issued with coverage until June 2043Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a
2y agoIMVTImmunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023GlobeNewswireImmunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year Immunovant plans to initiate trials in 10 indications for IMVT-1402 over the next two fiscal yearsInitial
2y agoIMVTImmunovant to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireNEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete
2y agoIMVTImmunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' DiseaseGlobeNewswireNEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from
2y agoIMVT ROIVRoivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' DiseaseGlobeNewswireNEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from
2y agoIMVT ROIVRoivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialGlobeNewswireResults from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to
2y agoIMVTImmunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialGlobeNewswireResults from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to
2y agoIMVTImmunovant to Present at Upcoming Investor ConferencesGlobeNewswireNEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete
3y agoIMVTImmunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023GlobeNewswirePositive initial Phase 1 data for IMVT-1402 announced, bolstering best-in-class potentialInitial 600 mg multiple-ascending dose (MAD) cohort data for IMVT-1402 expected in November 2023Initial Phase 2 proof-of-concept
3y agoIMVTImmunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireNEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the closing of its
3y agoIMVTImmunovant Announces Pricing of $450 Million Common Stock FinancingGlobeNewswireNEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an
3y agoIMVTImmunovant Announces Proposed Offering of $300 Million of Common StockGlobeNewswireNEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the commencement
3y agoIMVT ROIVRoivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD ResultsGlobeNewswireIMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimabNo decrease in serum albumin below baseline or increase in low-density
3y agoIMVTImmunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD ResultsGlobeNewswireIMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimabNo decrease in serum albumin below baseline or increase in low-density
3y agoIMVTImmunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023GlobeNewswireNEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will
3y agoIMVTImmunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023GlobeNewswireInitial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023 (single-ascending dose) and October/November 2023 (multiple-ascending dose) Phase 2 proof-of-concept data for batoclimab in Graves'
3y agoIMVTImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023GlobeNewswireInvestigational New Drug (IND) application and Clinical Trial Application (CTA) for IMVT-1402 cleared by the FDA and MEDSAFE, respectivelyPhase 1 clinical trial in healthy subjects initiated in New ZealandPhase 2